Tuesday January 21, 2020

Watchdog says expensive cancer drugs not delivering

Value for money criteria met by only one of 20 new drugs that had an initial asking price of €500 million

Susan Mitchell

Deputy Editor and Health Editor

15th October, 2017
A study has found that 57 per cent of new cancer drugs in Europe lack clear evidence that they extend or improve patients’ lives Pic: Shutterstock

Just one of 20 new cancer drugs examined by the state’s medicines watchdog was considered value for money, according to a new assessment by the body.

Professor Michael Barry, who heads up the National Centre for Pharmacoeoconomics (NCPE), said the assessment of cancer drugs raised “obvious questions” around how we decided to spend limited resources in the health service.

“The question has to be asked - would we be better spending such...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Breast screening is fallible, and with potential extra costs due to legal actions, questions about the viability of the programme are invevitable

John Crown | 2 days ago

Inquest report calls for 24-hour consultant cover after delay in treatment led to death of Wexford patient

Susan Mitchell | 1 week ago

HSE plans to implement HPV screening test ‘during Q1 this year’

Susan Mitchell | 1 week ago